HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,610
-80 (-0.45%)
Apr 29, 2026, 12:18 PM KST
-9.78%
Market Cap 248.41B
Revenue (ttm) 205.58B
Net Income (ttm) 4.57B
Shares Out 14.04M
EPS (ttm) 140.00
PE Ratio 126.36
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,632
Average Volume 149,481
Open 17,710
Previous Close 17,690
Day's Range 17,470 - 17,810
52-Week Range 12,500 - 22,250
Beta 0.39
RSI 54.99
Earnings Date May 15, 2026

About HLB Pharmaceutical

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, par... [Read more]

Sector Healthcare
Founded 1998
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 047920
Full Company Profile

Financial Performance

In 2025, HLB Pharmaceutical's revenue was 205.58 billion, an increase of 49.97% compared to the previous year's 137.08 billion. Earnings were 4.57 billion, an increase of 126.35%.

Financial Statements

News

There is no news available yet.